The item you just added is unavailable. Please select another product or variant.
Oxford University announces £10m study into CBD potential
If there’s one sure sign the world is waking up to the power of CBD, it’s when professors at Oxford University launch a research programme into the role of cannabinoids in biology and medicine.
The research is funded by Kingsley Capital Partners, through its portfolio company Oxford Cannabinoid Technologies. Studies have been underway since March 2017, and aim to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.
Although the medicinal properties of cannabis have been known since around 8000 BC, the plant’s potential has been curbed for almost a century. After years of lies and suspicion about cannabis and its effects, the world’s most respected medical minds are cutting through the condemnation. Finally, it seems, the tide is turning.
But now the world’s most respected institutions like Oxford University are investigating the plant’s capabilities, the long-standing discrimination is starting to fall away. It’s great news for legal, non-psychoactive derivatives like cannabis oil (CBD), which is once again becoming a legitimate everyday supplement to help with a range of conditions. Finally, CBD is getting the recognition it deserves.
Ahmed Ahmed, Professor of Gynaecological Oncology at Oxford, says, “Cannabinoid research has started to produce exciting biological discoveries, and this research programme is a timely opportunity to increase our understanding of the role of cannabinoids in health and disease. This field holds great promise for developing novel therapeutic opportunities for cancer patients.”